Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase (PARP) Inhibitors

Therapeutic drugs that block DNA repair, including poly(ADP-ribose) polymerase (PARP) inhibitors, fail due to lack of tumor-selectivity. When PARP inhibitors and β-lapachone are combined, synergistic antitumor activity results from sustained NAD(P)H levels that refuel NQO1-dependent futile redox dru...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Cell
Autori principali: Huang, Xiumei, Motea, Edward A., Moore, Zachary R., Yao, Jun, Dong, Ying, Chakrabarti, Gaurab, Kilgore, Jessica A., Silvers, Molly A., Patidar, Praveen L., Cholka, Agnieszka, Fattah, Farjana, Cha, Yoonjeong, Anderson, Glenda G., Kusko, Rebecca, Peyton, Michael, Yan, Jingsheng, Xie, Xian-Jin, Sarode, Venetia, Williams, Noelle S., Minna, John D., Beg, Muhammad, Gerber, David E., Bey, Erik A., Boothman, David A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161231/
https://ncbi.nlm.nih.gov/pubmed/27960087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.11.006
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi